Every 8-K that Crown Reserve Acquisition Corp. I Warrant (CRACW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CRACW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRACW filings page.
Crown Reserve Acquisition Corp. I (CRAC), its wholly owned subsidiary CRAC Merger Sub Inc., and Carvix, Inc. amended their agreement for a proposed business combination. Either CRAC or Carvix may terminate the agreement if the Effective Time has not occurred by the later of February 10, 2027 and the date CRAC is required under its Pre-Domestication Organizational Documents, as amended with shareholder approval, to complete a business combination. A party, including through its affiliates, cannot use this right if its breach or violation is the principal cause of a failed closing condition by the Outside Date.
The previous Outside Date was September 30, 2026. The proposed combination will be submitted to CRAC shareholders, and a registration statement is expected to include proxy statements and a prospectus relating to securities to be issued at closing. Other agreement terms remain in force.
Crown Reserve Acquisition Corp. I (CRAC) reports that it entered into a First Amendment to its Business Combination Agreement with CRAC Merger Sub Inc. and Carvix, Inc. on August 26, 2026. The amendment revises a covenant on shareholder approvals to align with the company’s Fourth Amended and Restated Memorandum and Articles of Association and clarifies that it does not change the voting rights of any security holder.
The amendment also clarifies that certain advisory organizational document proposals at the extraordinary general meeting are non-binding and not conditions to closing the business combination. In addition, it sets minimum annualized base salaries for specified Carvix executives in future employment agreements, tying bonus calculations to those base salary levels, while leaving the Carvix disclosure schedule otherwise unchanged. All other terms of the Business Combination Agreement remain in effect.
Crown Reserve Acquisition Corp. I entered a Business Combination Agreement with Carvix, Inc., under which Crown Reserve will domesticate from Cayman to Delaware and then merge a subsidiary into Carvix, leaving Carvix as a wholly owned subsidiary.
Carvix stockholders will receive an aggregate 50,000,001 shares of the post-combination company at closing, plus the right to earn up to an additional 50,000,100 shares over four fiscal years beginning January 1, 2027, based on EBITDA and revenue performance targets. The sponsor may also earn up to 3,000,000 shares over the first three years if specified milestones are met. Closing depends on stockholder approvals, SEC effectiveness of an S-4 registration statement, Nasdaq listing approval, antitrust clearance if required, minimum cash conditions and other customary requirements, with a potential outside date of September 30, 2026.